Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $3.99B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.91M
Average 2.67M
DFTX Sales of Investments
Cash received from selling or redeeming investments.
Definium Therapeutics, Inc.NASDAQ: DFTX
Sales of Investments · Q3 FY2026 · quarter ended Sep 2026
Sales of investments grows, but more slowly than its trailing trend
Q3 FY2026 sales of investments of $70M rose 66.7% year over year, behind the +355.0% change in trailing-twelve-month sales of investments. Sequentially, it rose 79.5% from the prior quarter.
Context
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +66.7% toward the trailing-twelve-month pace of +355.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 116.75M USD
- Year-over-year change
- —
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116.75M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Sales of Investments vs competitors
How DFTX compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +355.0% is the highest of 6, against a peer median of +31.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5B USD | — | — | — | |
| LTM Sep 2026 | $423.12M USD | +36.8% | +20.1% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $191.08M USD | +355.0% | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $171.77M USD | -36.5% | — | 858.8% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.63M USD | -44.8% | +51.8% | — |
| LTM Mar 2026 | $115.03M USD | +39.4% | — | — | |
| LTM Mar 2026 | $63.88M USD | +31.7% | — | — | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $0 USD | — | +243.9% | — |
| LTM Mar 2026 | $0 USD | — | — | — | |
| FY2025 | A$0 AUD | — | — | 0.0% | |
| Peer median (excluding DFTX) | — | +31.7% | +51.8% | 0.0% | |
Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.04M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Depreciation & Amortization | 2.62M | 3.18M | 3.16M | 527K | 0 |
| Deferred Income Tax | (1.16M) | 0 | (2.03M) | 0 | 0 |
| Stock-Based Compensation | 42.72M | 13.71M | 15.49M | 16.91M | 20.1M |
| Change in Working Capital | 1.88M | (3.78M) | 6.28M | (3.34M) | 9.44M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.28M | (2.06M) | 2.03M | (2.13M) | 3.34M |
| Other Working Capital | 598K | (1.73M) | 4.26M | (1.22M) | 6.1M |
| Other Non-Cash Items | 1.16M | (6.45M) | 8.46M | 15.45M | 22.7M |
| Operating Cash Flow | (45.82M) | (50.14M) | (64.37M) | (79.13M) | (131.56M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | (297K) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (268.36M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 116.75M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (297K) | 0 | 0 | 0 | (151.61M) |
| Debt Repayment | 0 | 0 | 14.16M | 10.86M | 20M |
| Common Stock Issued | 81.92M | 42.3M | 7.53M | 250M | 259.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.9M | 16.75M | 163K | (7.66M) | (12.63M) |
| Financing Cash Flow | 98.82M | 59.05M | 21.85M | 253.2M | 267.27M |
| Effect of Forex Changes | 742K | (309K) | 79K | (30K) | (7K) |
| Net Change in Cash | 53.45M | 8.6M | (42.44M) | 174.04M | (15.9M) |
| Free Cash Flow | (45.82M) | (50.14M) | (64.37M) | (79.13M) | (131.56M) |
Definium Therapeutics, Inc.
NASDAQ:DFTX
Intrinsic Alpha fair value
Locked
Current Price
$29.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.